Medical News

RSS

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

Afghanistan's geography is dominated by a collection of craggy peaks, the highest-a mountain known as Noshaq-has been measured to 7,492 meters. Consequently, the soldiers on duty in this mountainous terrain must often ascend to great heights as part of their duty.

22 Apr 2013

Advances in treatment have improved the chances of survival for young patients with cancer

Over the years, advances in treatment have improved the chances of survival for young patients with cancer. But long-term survivors need to be aware of cancer treatments that may place them at increased risk of heart disease later in life.

22 Apr 2013

Loss or amplification of particular DNA regions contributes to the development of prostate cancer

A new analysis has found that the loss or amplification of particular DNA regions contributes to the development of prostate cancer, and that patients with two of these DNA changes have a high likelihood of dying from the disease.

22 Apr 2013

FDA clears Aspect's M2 compact MRI system for diagnostic imaging of wrist

Aspect Imaging, the world leading developer of compact high-performance magnets, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's M2 compact MRI system for diagnostic imaging of the wrist.

22 Apr 2013

Study: Anesthesia increases success rates of version procedures, decreases cost of delivery

When a baby is in the breech position at the end of pregnancy, obstetricians can sometimes turn the baby head-down to enable a safer vaginal birth.

22 Apr 2013

Study provides medical chemists with tools to design safer drugs, predict their side effects

Yellow vision, pseudo-pulmonary obstruction, involuntary body movements, respiratory paralysis. These are some of the 1,600 known side effects (SEs) produced by drugs.

22 Apr 2013

Vaginal infections can be treated and prevented using Cranberry-Active tablets

Dutch Medical Brands receives first European Class IIa Medical Device Status to treat vaginal infections by using cranberry extracts.

22 Apr 2013

New licensing agreement to promote discovery in health IT and improve economic Growth

The Regenstrief Institute Inc., an international leader in electronic medical records and health information exchange research, development and operations, is licensing its Indiana Network for Patient Care and DOCS4DOCS clinical results delivery software to a subsidiary of the Indiana Health Information Exchange. This licensing agreement represents the single most significant transfer of discovery out of an academic medical informatics research setting to a commercial enterprise in the history of Indiana's health information technology sector and the national evolution of health information exchange.

22 Apr 2013

Selenium research performed by Dr. Joel Wallach continues to be at the forefront of health and prevention

Youngevity® Essential Life Sciences, a wholly-owned subsidiary of AL International, Inc., announces that the research of Youngevity® founder, Dr. Joel D. Wallach, BS, DVM, ND, on Selenium continues to be at the forefront of health and prevention with the recent U.S. Food and Drug Administration (FDA) proposed rule requiring the addition of selenium to the list of required nutrients for infant formula products.

22 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the first patient has been dosed in a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer coordinated by the Brown University Oncology Research Group (BrUOG).

22 Apr 2013

Advaxis to license its ADXS-HPV product candidate to FusionVax

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has entered into a Memorandum of Understanding (MoU) with FusionVax, Inc. ("FusionVax") setting forth the main terms under which Advaxis will, subject to the entry of a definitive agreement, exclusively license its lead clinical stage product candidate, ADXS-HPV, to FusionVax for Asia.

22 Apr 2013

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Pioneering research led by Johns Hopkins scientists on the use of partially matched bone marrow transplants to wipe out sickle cell disease has been selected as one of the Top 10 Clinical Research Achievements of 2012 by the Clinical Research Forum.

22 Apr 2013

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Synta Pharmaceuticals Corp. announced today that the first patients have been treated in the randomized GALAXY-2 Phase 3 trial designed to evaluate docetaxel plus ganetespib, its investigational Hsp90 inhibitor, versus docetaxel alone for the second-line treatment of non-small cell lung adenocarcinoma.

22 Apr 2013

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Xenon Pharmaceuticals Inc. is pleased to announce that it has been awarded BIOTECanada's Gold Leaf Company of the Year Award for 2013.

22 Apr 2013

Janssen Diabetes Forum: A medical education initiative for management of type 2 diabetes

Launched today in Beerse, the Janssen Diabetes Forum (www.janssendiabetesforum.com) is a novel medical education initiative, which has been developed to contribute to the understanding of the latest developments in the management of type 2 diabetes.

22 Apr 2013

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of a research study, conducted with an independent market research firm, that identified a significant unmet medical need for improved treatments for patients with chronic pain and dysphagia/odynophagia. In clinical practice, dysphagia is most often defined as difficulty in swallowing and odynophagia is defined as pain upon swallowing.

22 Apr 2013

Medical News

Researchers suggest two days of staging at moderate altitude reduces acute mountain sickness

Advances in treatment have improved the chances of survival for young patients with cancer

Loss or amplification of particular DNA regions contributes to the development of prostate cancer

FDA clears Aspect's M2 compact MRI system for diagnostic imaging of wrist

Study: Anesthesia increases success rates of version procedures, decreases cost of delivery

Study provides medical chemists with tools to design safer drugs, predict their side effects

Vaginal infections can be treated and prevented using Cranberry-Active tablets

New licensing agreement to promote discovery in health IT and improve economic Growth

Selenium research performed by Dr. Joel Wallach continues to be at the forefront of health and prevention

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Advaxis completes ADXS-HPV Phase 1/2 dosing in patients with HPV-associated anal cancer

Advaxis to license its ADXS-HPV product candidate to FusionVax

Clinical Research Forum selects sickle cell project among 'Top 10' clinical research achievements of 2012

Synta completes GALAXY-2 trial evaluating ganetespib inhibitor in non-small cell lung cance

Xenon Pharmaceuticalsn receives BIOTECanada's Gold Leaf Company of the Year Award for 2013

Janssen Diabetes Forum: A medical education initiative for management of type 2 diabetes

Study indentifies unmet medical need for treatment of patients with chronic pain and dysphagia

Investigator honored for advancing osteoporosis research and advocacy worldwide

Aurigene and Endo’s collaborative efforts yield novel drug candidates

Avinger and PDL BioPharma close structured financing and royalty transaction

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News